Preliminary Studies of Neuropilin-1 Expression on HCC and Inhibitive Effect of Anti-NRP-1 Monoclonal Antibody on HCC Growth by 张亚飞
  
 
学校编码：10384                             分类号      密级        




   硕  士  学  位  论  文 
                                           
Neuropilin-1 在肝癌中的表达及其单克隆抗
体对肝癌生长抑制作用的初步研究 
Preliminary Studies of Neuropilin-1 Expression on HCC and 





指  导 教 师： 苏新辉  教授 
专  业 名 称： 影像医学与核医学 
论文提交日期：2015年  5月 
论文答辩时间：2015年  5月 
学位授予日期：2015年  6月 
答辩委员会主席：           
评    阅    人：           



















另外，该学位论文为（                           ）课题（组）
的研究成果，获得（               ）课题（组）经费或实验室的





      年   月   日 
 



































（     ）1.经厦门大学保密委员会审查核定的保密学位论文，
于   年  月  日解密，解密后适用上述授权。 






                             声明人（签名）： 

































本文主要研究 NRP-1 与肝细胞癌恶性程度的相关性及抗 NRP-1 抗体对抗肿瘤的
活性。 
实验方法 





测 NRP-1 mAb对肝癌细胞株增殖的影响；流式细胞术检测 NRP-1 mAb 对肝癌细















并通过免疫组化观察治疗后肿瘤内 NRP-1 和 VEGF 的表达以及微血管密度的变












恶性程度相关。NRP-1 mAb可与肝癌细胞及组织上 NRP-1特异性结合。 
2. NRP-1 mAb可以抑制肝癌细胞增殖、集落形成并诱导凋亡，具有明显的抗
肿瘤活性。NRP-1 mAb是一个具有前景的抗肿瘤候选药物。 
3. NRP-1 mAb 可以特异性定位于荷瘤鼠肿瘤部位并对肿瘤有一定的抑制作
用。 




























Liver cancer, one of the main malignant tumors, is harmful to human. Liver 
cancer in men is the fifth most frequently diagnosed cancer worldwide but the second 
most frequent cause of cancer death. In women, it is the seventh most commonly 
diagnosed cancer and the sixth leading cause of cancer death. Hepatocellular 
carcinoma (HCC) accounted for 70% of all the liver cancer, and the diagnosis and 
treatment of HCC depend on various factors. Only patients with early diagnosis of 
HCC could be beneficial to the treatment of resection or transplantation. Most HCC 
patients are not suitable for radical surgery for the late diagnosis, and the prognosis of 
HCC was unsatisfactory. Traditional therapy are used in a restrict range for the 
disadvantages of low effects and large side effects. Molecular targeted drugs with 
high tumor-targeting ability and low side effects provide a new strategy for HCC. The 
complexity of the HCC etiology and pathogenesis, lesion sites of different patients are 
also various, therefore, finding new targets and new drugs for HCC cancer is very 
important. Neuropilin-1 (NRP-1) is a non-tyrosine kinase receptor for Semaphorin 3A 
(Sema 3A) and vascular endothelial growth factor (VEGF) involved in tumor 
angiogenesis, growth and metastasis. NRP-1 is high expressed in multiple tumors 
including HCC, which is closely related to the tumor malignant degree and regarded 
as a promising target for cancer therapy. In present study, we investigated the 
expression of NRP-1 on HCC and the anti-tumor effects of anti-NRP-1 mAb on HCC. 
Methods   
Firstly, flow cytometry was used to observe combination ability of anti-NRP-1 
mAb to Bel7402, HepG2, SMMC-7721 cells and the NRP-1 expression on these HCC 
cells, immunofluorescence and immunocytochemistry were used to observe the 
localization of anti-NRP-1mAb in the cells, immunohistochemistry was used to 















between NRP-1 expression and the malignant degree of HCC. Then MTT was used to 
evaluate the inhibitory effect of NRP-1 mAb on proliferation. Cell morphology was 
observed by microscopy. Flow cytometry were used to observe cell apoptosis. 
131
I 
labeled NRP-1 mAb was used to detected the targeting and specificity of NRP-1 mAb 
in the tumor-burdened nude mice mode, and NRP-1 mAb was injected via the tail 
vein to explore its the curative effect. Immunohistochemical was conducted to 
obverse the NRP-1 and VEGF expressions as well as the change of MVD after 
treatment. 
Results 
Western blotting showed the bands of 130 KDa indicating the NRP-1 mAb could 
bind to both recombinant NRP-1 b1b2 and full-length NRP-1 in cancer cells. Flow 
cytometry showed that HCC cell lines positively expressed NPR-1 on various levels. 
Immunofluorescence and immunocytochemical experiments results showed that the 
anti-NRP-1 mAb localizated on the cell surface, immunohistochemical experiment 
results showed that the expression of NRP-1 was positively correlated with the tumor 
grading. MTT and colony forming assay showed that NRP-1 mAb have inhibitory 
effect on the HCC cell lines in dose-dependent method and time-dependent method. 
Flow cytometry showed that NRP-1 mAb led to apoptosis of HCC cell lines in 
dose-dependent method. Experiments on nude models proved the anti-NRP-1 mAb 
could be localization on the tumor in vivo and plays an important role on tumor 
treatment. 
Conclusions 
(1) NRP-1 was overexpression on different HCC cell lines with different levels and  
NRP-1 mAb can bind to the NRP-1 expressed in the HCC cell lines, in addition, the 
NRP-1 expression was related to the tumor malignant degree.  
(2) NRP-1 mAb could be located in the tumor in vivo and has certain effect on tumor 
treatment.  
(3) NRP-1 mAb have inhibitory effect on the HCC cell lines in dose-dependent 
method and time-dependent method. 
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